Citations

Showing 10 of 108083 citations.

A Novel Signaling Complex between TROY and EGFR Mediates Glioblastoma Cell Invasion
Ding, Zonghui , Roos, Alison , Kloss, Jean , Peng, Sen, Pirrotte, Patrick , Eschbacher, Jennifer M., Tran, Nhan L. , Loftus, Joseph C. , Dhruv, Harshil , Tran, Nhan L

Mayo Clinic

Molecular Cancer Research | November 8, 2017 | Volume: 16 | Issue: 2 | Pages: 322-332

10.1158/1541-7786.mcr-17-0454 | PMID 29117939 Get It

Abstract Glioblastoma is the most frequent primary brain tumor in adults and a highly lethal malignancy with a median survival of about 15 months. The aggressive invasion of the surrounding normal brain makes complete surgical resection impossible, increases the resistance to radiation and chemotherapy, and assures tumor recurrence. Thus, there is an urgent need to develop innovative therapeutics to target the invasive tumor cells for improved treatment outcomes of this disease. Expression of TROY (TNFRSF19), a member of the tumor necrosis factor (TNF) receptor family, increases with increasing glial tumor grade and inversely correlates with patient survival. Increased expression of TROY stimulates glioblastoma cell invasion in vitro and in vivo and increases resistance to temozolomide and radiation therapy. Conversely, silencing TROY expression inhibits glioblastoma cell invasion, increases temozolomide sensitivity, and prolongs survival in an intracranial xenograft model. Here, a novel complex is identified between TROY and EGFR, which is mediated predominantly by the cysteine-rich CRD3 domain of TROY. Glioblastoma tumors with elevated TROY expression have a statistically positive correlation with increased EGFR expression. TROY expression significantly increases the capacity of EGF to stimulate glioblastoma cell invasion, whereas depletion of TROY expression blocks EGF stimulation of glioblastoma cell invasion. Mechanistically, TROY expression modulates EGFR signaling by facilitating EGFR activation and delaying EGFR receptor internalization. Moreover, the association of EGFR with TROY increases TROY-induced NF-κB activation. These findings substantiate a critical role for the TROY–EGFR complex in regulation of glioblastoma cell invasion. Implications: The TROY–EGFR signaling complex emerges as a potential therapeutic target to inhibit glioblastoma cell invasion. Mol Cancer Res; 16(2); 322–32. ©2017 AACR.
Assessment of Fluorodeoxyglucose F18–Labeled Positron Emission Tomography for Diagnosis of High-Risk Lung Nodules
Deppen, Stephen A. , Mercaldo, Sarah , Blume, Jeffrey D. , Montgomery, Chandler , Vaszar, Laszlo T. , Isbell, James M. , Rickman, Otis B. , Pinkerman, Rhonda, Lambright, Eric S., Nesbitt, Jonathan C., Grogan, Eric L. , Maiga, Amelia Walling , Williamson, Christina

Mayo Clinic

JAMA Surgery | November 8, 2017 | Volume: 153 | Issue: 4 | Pages: 329

10.1001/jamasurg.2017.4495 | PMID 29117314 Get It

Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH
Pol, Atze van der , Gil, Andrés , Silljé, Herman H.W. , Tromp, Jasper , Ovchinnikova, Ekaterina S. , Vreeswijk‐Baudoin, Inge, Hoes, Martijn F. , Domian, Ibrahim J., Sluis, Bart van de , Deursen, Jan M. van , Veldhuisen, Dirk J. van , Gilst, Wiek H. van , Berezikov, Eugène , Harst, Pim van der , Boer, Rudolf A. de , Bischoff, Rainer , Meer, Peter van der , van der Pol, Atze , van Deursen, Jan M , van Gilst, Wiek H , Berezikov, Eugene , van der Harst, Pim , de Boer, Rudolf A , Bischoff, Rainer , van der Meer, Peter , van de Sluis, Bart , Voors, Adriaan A.

Mayo Clinic

Science Translational Medicine | November 8, 2017 | Volume: 9 | Issue: 415 | Pages: No page available

10.1126/scitranslmed.aam8574 | PMID 29118264 Get It

OPLAH is cardioprotective for myocardial infarction, and its substrate 5-oxoproline is a putative circulating marker for heart failure.
Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy
Ayed, Ayed O. , Ayed, Ayed , Parikh, Sameer A.

Mayo Clinic

Leukemia & Lymphoma | November 8, 2017 | Volume: 59 | Issue: 10 | Pages: 2287-2296

10.1080/10428194.2017.1397665 | PMID 29115892 Get It

What Constitutes Experience in Surgical Treatment of Valve Disease and How Important Is It?
Schaff, Hartzell V. , Schaff, Hartzell

Mayo Clinic

JAMA Cardiology | November 8, 2017 | Volume: 2 | Issue: 12 | Pages: 1299

10.1001/jamacardio.2017.4004 | PMID 29117284 Get It

Conflicting Goals: You Can't Always Get What You Want—But If You Try, You Might Get What You Need
Moore, Michael, Rich, Shayna E., Moore, Michael D

Mayo Clinic

Journal of Palliative Medicine | November 8, 2017 | Volume: 21 | Issue: 4 | Pages: 572-573

10.1089/jpm.2017.0550 | PMID 29115908 Get It

Impact of hypercortisolism on skeletal muscle mass and adipose tissue mass in patients with adrenal adenomas
Delivanis, Danae A. , Iñiguez‐Ariza, Nicole M. , Zeb, Muhammad, Moynagh, Michael R., Takahashi, Naoki , McKenzie, Travis J. , Thomas, Melinda, Gogos, Charalambos, Kyriazopoulou, Venetsana, Zeb, Muhammad H, Thomas, Melinda A, Young, William F. , Bancos, Irina , Takahashi, Naoki

Mayo Clinic

Clinical Endocrinology | November 8, 2017 | Volume: 88 | Issue: 2 | Pages: 209-216

10.1111/cen.13512 | PMID 29115003 Get It

SummaryContextAbdominal visceral adiposity and central sarcopenia are markers of increased cardiovascular risk and mortality.ObjectiveTo assess whether central sarcopenia and adiposity can serve as a marker of disease severity in patients with adrenal adenomas and glucocorticoid secretory autonomy.DesignRetrospective cohort study.PatientsTwenty‐five patients with overt Cushing's syndrome (CS), 48 patients with mild autonomous cortisol excess (MACE) and 32 patients with a nonfunctioning adrenal tumour (NFAT) were included.MethodsMedical records were reviewed, and body composition measurements (visceral fat [VAT], subcutaneous fat [SAT], visceral/total fat [V/T], visceral/subcutaneous [V/S] and total abdominal muscle mass) were calculated based on abdominal computed tomography (CT).ResultsIn patients with overt CS, when compared to patients with NFAT, the V/T fat and the V/S ratio were increased by 0.08 (P < .001) and by 0.3 (P < .001); however, these measurements were decreased by 0.04 (P = .007) and 0.2 (P = .01), respectively, in patients with MACE. Total muscle mass was decreased by −10 cm2 (P = .02) in patients with overt CS compared to patients with NFAT. Correlation with morning serum cortisol concentrations after dexamethasone suppression testing revealed that for every 28 nmol/L cortisol increase there was a 0.008 increase in V/T (P < .001), 0.02 increase in the V/S fat ratio (P < .001) and a 1.2 cm2 decrease in mean total muscle mass (P = .002).ConclusionsThe severity of hypercortisolism was correlated with lower muscle mass and higher visceral adiposity. These CT‐based markers may allow for a more reliable and objective assessment of glucocorticoid‐related disease severity in patients with adrenal adenomas.
Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer
Ahn, Daniel H. , Reardon, Josh, Bupathi, Manojkumar , Mikhail, Sameh , Wu, Christina Sing‐Ying, Bekaii‐Saab, Tanios , Bekaii-Saab, Tanios S , Ahn, Chul Woo

Mayo Clinic

International Journal of Cancer | November 8, 2017 | Volume: 142 | Issue: 8 | Pages: 1671-1675

10.1002/ijc.31144 | PMID 29114851 Get It

Treatment with cisplatin and gemcitabine demonstrates a survival benefit in patients with advanced biliary tract cancer (ABTC). However, the weekly administration can add significant toxicities that may prohibit prolonged treatment. Based on previous studies, we implemented a modified biweekly regimen of GC in an attempt to optimize the prescribed regimen with an improved toxicity profile, added convenience to patients while maintaining efficacy. Patients with ABTC were treated with fixed dose rate (FDR) gemcitabine (1,000 mg/m2/min) and cisplatin 20 mg/m2 on days 1 and 15 of every 28‐day cycle. Patients received treatment until time of progression, death, or discontinuation due to intolerance. Collected data included demographics, clinico‐pathologic features, toxicities, and survival. Kaplan‐Meier curves were used to calculate the median overall survival (OS) and progression free survival (PFS). The study included 107 evaluable pts with unresectable ABTC who received the biweekly regimen. Sites of tumor included gallbladder (21.5%), ampullary (3.7%), and bile duct (74.8%). Median number of cycles was 6 (1–27). Median PFS was 8.34 (6.74, 9.23) months and median OS was 10.32 (9.10, 11.43) months. Most common grade ≥3 adverse events included neutropenia (11%), fatigue (10%), and thrombocytopenia (6.4%). Biweekly FDR GC in ABTC is associated with a more favorable toxicity profile while maintaining efficacy similar to that observed in prior clinical trials. Minimal toxicities were observed despite a prolonged course for many patients. Further prospective trials should consider evaluating the role of biweekly GC regimen in ABTC, including a potentially more favorable platform in novel experimental strategies.
The biology and mathematical modelling of glioma invasion: a review
Alfonso, Juan Carlos López , Talkenberger, Katrin, Seifert, Michael , Klink, Barbara , Swanson, Kristin R. , Hatzikirou, Haralampos , Deutsch, Andreas , Alfonso, J C L , Deutsch, A , Swanson, Kristin R , Hawkins‐Daarud, Andrea

Mayo Clinic

Journal of The Royal Society Interface | November 8, 2017 | Volume: 14 | Issue: 136 | Pages: 20170490

10.1098/rsif.2017.0490 | PMID 29118112 Get It

Adult gliomas are aggressive brain tumours associated with low patient survival rates and limited life expectancy. The most important hallmark of this type of tumour is its invasive behaviour, characterized by a markedly phenotypic plasticity, infiltrative tumour morphologies and the ability of malignant progression from low- to high-grade tumour types. Indeed, the widespread infiltration of healthy brain tissue by glioma cells is largely responsible for poor prognosis and the difficulty of finding curative therapies. Meanwhile, mathematical models have been established to analyse potential mechanisms of glioma invasion. In this review, we start with a brief introduction to current biological knowledge about glioma invasion, and then critically review and highlight future challenges for mathematical models of glioma invasion.